Releases
FSTX
--
0.00%
--
  • All
  • Financials
  • Insiders
More
Webull provides the latest F-star Therapeutics Inc (FSTX) stock and general news. This information may help you make smarter investment decisions.
About FSTX
F-Star Therapeutics, Inc., formerly Spring Bank Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics for the treatment of viral infections, inflammatory diseases and cancers using its small molecule nucleotide platform. The Company is developing its product inarigivir soproxil (inarigivir), for the treatment of chronic hepatitis B virus (HBV). The Company's inarigivir selectively activates within infected hepatic cells the cellular protein, retinoic acid-inducible gene 1 (RIG-I), to inhibit viral replication and to cause the induction of intracellular interferon signaling pathways for antiviral defense. The Company also developing a second STING (STimulator of INterferon Genes) agonist product candidate, SB 11285, which is an immunotherapeutic agent for the potential treatment of selected cancers. The Company lead product is inarigivir.